BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 2693029)

  • 21. Characterization of beta-cell function impairment in first-degree relatives of type 2 diabetic subjects: modeling analysis of 24-h triple-meal tests.
    Mari A; Gastaldelli A; Natali A; Ostergard T; Schmitz O; Ferrannini E
    Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E541-6. PubMed ID: 15522997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hormonal Responses to Cholinergic Input Are Different in Humans with and without Type 2 Diabetes Mellitus.
    Chowdhury S; Wang S; Dunai J; Kilpatrick R; Oestricker LZ; Wallendorf MJ; Patterson BW; Reeds DN; Wice BM
    PLoS One; 2016; 11(6):e0156852. PubMed ID: 27304975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of synthetic human glucose-dependent insulinotropic polypeptide (hGIP) on the release of insulin in man.
    Füessl HS; Yiangou Y; Ghatei MA; Goebel FD; Bloom SR
    Eur J Clin Invest; 1990 Oct; 20(5):525-9. PubMed ID: 2124984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes.
    Højberg PV; Vilsbøll T; Zander M; Knop FK; Krarup T; Vølund A; Holst JJ; Madsbad S
    Diabet Med; 2008 Nov; 25(11):1268-75. PubMed ID: 19046215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gastric inhibitory polypeptide responses and glucose turnover rates after natural meals in type II diabetic patients.
    Osei K; Falko JM; O'Dorisio TM; Fields PG; Bossetti B
    J Clin Endocrinol Metab; 1986 Feb; 62(2):325-30. PubMed ID: 3510224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus.
    Shapiro ET; Van Cauter E; Tillil H; Given BD; Hirsch L; Beebe C; Rubenstein AH; Polonsky KS
    J Clin Endocrinol Metab; 1989 Sep; 69(3):571-6. PubMed ID: 2503533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fasting and oral glucose-stimulated levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are highly familial traits.
    Gjesing AP; Ekstrøm CT; Eiberg H; Urhammer SA; Holst JJ; Pedersen O; Hansen T
    Diabetologia; 2012 May; 55(5):1338-45. PubMed ID: 22349073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.
    Elahi D; McAloon-Dyke M; Fukagawa NK; Meneilly GS; Sclater AL; Minaker KL; Habener JF; Andersen DK
    Regul Pept; 1994 Apr; 51(1):63-74. PubMed ID: 8036284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes.
    Alsalim W; Tura A; Pacini G; Omar B; Bizzotto R; Mari A; Ahrén B
    Diabetes Obes Metab; 2016 Jan; 18(1):24-33. PubMed ID: 26354383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancement of insulin secretory response to glucose-dependent insulinotropic polypeptide (GIP) by growth hormone in dogs.
    Pierluissi J; de Pierluissi R; de Martínez A
    Acta Cient Venez; 2002; 53(1):29-35. PubMed ID: 12216497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes.
    Christensen MB; Calanna S; Holst JJ; Vilsbøll T; Knop FK
    J Clin Endocrinol Metab; 2014 Mar; 99(3):E418-26. PubMed ID: 24423311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects.
    Meier JJ; Gallwitz B; Kask B; Deacon CF; Holst JJ; Schmidt WE; Nauck MA
    Diabetes; 2004 Dec; 53 Suppl 3():S220-4. PubMed ID: 15561915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans.
    Veedfald S; Vedtofte L; Skov-Jeppesen K; Deacon CF; Hartmann B; Vilsbøll T; Knop FK; Christensen MB; Holst JJ
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31665480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucose-dependent insulinotropic polypeptide and insulin-like immunoreactivity in saliva following sham-fed and swallowed meals.
    Messenger B; Clifford MN; Morgan LM
    J Endocrinol; 2003 Jun; 177(3):407-12. PubMed ID: 12773121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.
    Højberg PV; Vilsbøll T; Rabøl R; Knop FK; Bache M; Krarup T; Holst JJ; Madsbad S
    Diabetologia; 2009 Feb; 52(2):199-207. PubMed ID: 19037628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
    J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of endogenous GIP in patients with type 2 diabetes.
    Stensen S; Gasbjerg LS; Krogh LL; Skov-Jeppesen K; Sparre-Ulrich AH; Jensen MH; Dela F; Hartmann B; Vilsbøll T; Holst JJ; Rosenkilde MM; Christensen MB; Knop FK
    Eur J Endocrinol; 2021 May; 185(1):33-45. PubMed ID: 33886495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.
    Aaboe K; Knop FK; Vilsboll T; Vølund A; Simonsen U; Deacon CF; Madsbad S; Holst JJ; Krarup T
    J Clin Endocrinol Metab; 2009 Feb; 94(2):603-8. PubMed ID: 19050053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
    Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
    J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.